Healthcare

A triple-digit percentage jump always looks arresting on a screener, but context matters, and few names make that point better than ViaDerma, Inc. (OTC:VDRM). The topical-drug-delivery company trades at a small fraction of a cent on the over-the-counter market, so an eye-catching one-day surge …

● The daily decline lacks a single verifiable catalyst; sharp percentage swings are typical for a micro-cap biotech with a modest market value.

● Tonix Pharmaceuticals Holding has spent the past year transforming from a perennially loss-making clinical-stage biotech into a company with an approved, commercially selling central-nervous-system product.

Clinical-stage biotech can turn on a single strategic decision, and Tempest Therapeutics, Inc (NASDAQ: TPST) has spent 2026 illustrating exactly that. Once defined by its liver-cancer candidate amezalpat, the Nasdaq-listed micro-cap has pivoted toward a next-generation cell-therapy strategy while its share price has collapsed …

● The modest decline of roughly 2% on September 9, 2026 has no single, clearly identifiable public catalyst.

Therapeutic Solutions International, Inc (OTC:TSOI) has long occupied the speculative end of the biotech spectrum: a clinical-stage, over-the-counter company with a broad pipeline of ideas but a share price sitting at a fraction of a penny. The most consequential recent development is not a …

That Marketing Solution, Inc. (OTC:TSTS) is the kind of ticker that rarely surfaces in mainstream market coverage: a tiny, development-stage consumer-products shell whose shares change hands, when they trade at all, at a fraction of a cent.